Premium
Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
Author(s) -
Waldherr Linda,
Seitanidou Maria,
Jakešová Marie,
Handl Verena,
Honeder Sophie,
Nowakowska Marta,
Tomin Tamara,
Karami Rad Meysam,
Schmidt Tony,
Distl Joachim,
BirnerGruenberger Ruth,
Campe Gord,
Schäfer Ute,
Berggren Magnus,
Rinner Beate,
Asslaber Martin,
GhaffariTabriziWizsy Nassim,
Patz Silke,
Simon Daniel T.,
Schindl Rainer
Publication year - 2021
Publication title -
advanced materials technologies
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.184
H-Index - 42
ISSN - 2365-709X
DOI - 10.1002/admt.202001302
Subject(s) - spheroid , temozolomide , u87 , glioblastoma , cancer research , blood–brain barrier , chemotherapy , brain tumor , adjuvant , medicine , gemcitabine , drug delivery , targeted therapy , cell , cell culture , chemistry , cancer , biology , oncology , pathology , central nervous system , biochemistry , genetics , organic chemistry
Successful treatment of glioblastoma multiforme (GBM), the most lethal tumor of the brain, is presently hampered by (i) the limits of safe surgical resection and (ii) “shielding” of residual tumor cells from promising chemotherapeutic drugs such as Gemcitabine (Gem) by the blood brain barrier (BBB). Here, the vastly greater GBM cell‐killing potency of Gem compared to the gold standard temozolomide is confirmed, moreover, it shows neuronal cells to be at least 10 4 ‐fold less sensitive to Gem than GBM cells. The study also demonstrates the potential of an electronically‐driven organic ion pump (“GemIP”) to achieve controlled, targeted Gem delivery to GBM cells. Thus, GemIP‐mediated Gem delivery is confirmed to be temporally and electrically controllable with pmol min −1 precision and electric addressing is linked to the efficient killing of GBM cell monolayers. Most strikingly, GemIP‐mediated GEM delivery leads to the overt disintegration of targeted GBM tumor spheroids. Electrically‐driven chemotherapy, here exemplified, has the potential to radically improve the efficacy of GBM adjuvant chemotherapy by enabling exquisitely‐targeted and controllable delivery of drugs irrespective of whether these can cross the BBB.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom